# OnCo record circle-pharma (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/circle-pharma/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "circle-pharma" ;
  schema:name "Circle Pharma"@en ;
  schema:description "Circle Pharma is developing CID-078, the first oral cyclin A/B RxL inhibitor, aimed at cancers with a broken G1/S checkpoint such as small-cell lung and triple-negative breast cancer."@en ;
  schema:url <https://onco.cc/companies/circle-pharma/>, <https://circlepharma.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://circlepharma.com/circle-pharma-to-present-new-clinical-and-preclinical-data-at-aacr-2026> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/cdk4-6/> ;
  onco:pathways <https://onco.cc/pathways/p53-cell-cycle/> .